GlassScriptPhysician profile
Bozena Witek
NPI 1275639585
$14,398.52
in general payments reported to CMS, 2019-2025
77 companies · $2,403 in 2025
The $2,403 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,145 · 2020: $822 · 2021: $1,838 · 2022: $1,810 · 2023: $2,575 · 2024: $2,805 · 2025: $2,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,771 · Education: $11.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,770.91 |
| Education | $11.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,050.61 | 2019-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals LP | $1,087.52 | 2019-2025 | Lynparza, Tagrisso, Imfinzi |
| Merck Sharp & Dohme LLC | $852.30 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $845.63 | 2019-2025 | Venclexta, Itovebi, Alecensa |
| Pfizer INC. | $739.73 | 2019-2025 | |
| Celgene Corporation | $736.80 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $685.85 | 2019-2025 | Opdivo, Opdualag |
| Abbvie INC. | $638.30 | 2019-2025 | Venclexta |
| Gilead Sciences, INC. | $605.62 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $402.77 | 2019-2025 | Vyloy, Xospata, Xtandi |
| Amgen INC. | $372.27 | 2019-2023 | Lumakras, Blincyto |
| Seagen INC. | $352.04 | 2019-2023 | Tukysa, Padcev |
| Incyte Corporation | $322.73 | 2021-2025 | Monjuvi, Jakafi |
| Tg Therapeutics, INC. | $306.38 | 2021 | |
| Glaxosmithkline, LLC. | $267.10 | 2022-2025 | Ojjaara, Zejula, Jemperli |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bozena Witek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.